• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗帕金森病的神经营养因子。

Neurotrophic factors for the treatment of Parkinson's disease.

机构信息

Department of Anatomy/Neuroscience, University College Cork, College Road, Cork, Ireland.

出版信息

Cytokine Growth Factor Rev. 2011 Jun;22(3):157-65. doi: 10.1016/j.cytogfr.2011.05.001.

DOI:10.1016/j.cytogfr.2011.05.001
PMID:21689963
Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder caused by the progressive degeneration of the nigrostriatal dopaminergic pathway. The resulting loss of dopamine neurotransmission is responsible for the symptoms of the disease. Available treatments are initially successful in treating PD symptoms; however, their long-term use is associated with complications and they cannot stop the neurodegeneration. Current research aims at developing new therapies to halt/reverse the neurodegenerative process, rather than treating symptoms. Neurotrophic factors are proteins critical for maintenance and protection of neurones in the developing and adult brain. Several neurotrophic factors have been investigated for their protective effects on dopaminergic neurones. Here we review some of the most promising factors and provide an update on their status in clinical trials.

摘要

帕金森病(PD)是一种常见的神经退行性疾病,由黑质纹状体多巴胺能通路的进行性退化引起。多巴胺神经递质传递的丧失是导致疾病症状的原因。现有的治疗方法在治疗 PD 症状方面最初是成功的;然而,它们的长期使用与并发症有关,并且不能阻止神经退行性变。目前的研究旨在开发新的治疗方法来阻止/逆转神经退行性过程,而不是治疗症状。神经营养因子是对发育中和成年大脑中的神经元的维持和保护至关重要的蛋白质。已经研究了几种神经营养因子对多巴胺能神经元的保护作用。在这里,我们回顾了一些最有前途的因素,并提供了它们在临床试验中的最新状况。

相似文献

1
Neurotrophic factors for the treatment of Parkinson's disease.用于治疗帕金森病的神经营养因子。
Cytokine Growth Factor Rev. 2011 Jun;22(3):157-65. doi: 10.1016/j.cytogfr.2011.05.001.
2
The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.神经营养因子在帕金森病治疗中的治疗潜力。
Exp Neurol. 1993 Nov;124(1):103-18. doi: 10.1006/exnr.1993.1181.
3
Neurotrophic factors for the treatment of Parkinson's disease.用于治疗帕金森病的神经营养因子。
Parkinsonism Relat Disord. 2007;13 Suppl 3:S321-8. doi: 10.1016/S1353-8020(08)70024-5.
4
Neurotrophic factors and Parkinson's disease: the emergence of a new player?神经营养因子与帕金森病:一位新角色的出现?
Sci STKE. 2007 Nov 6;2007(411):pe60. doi: 10.1126/stke.4112007pe60.
5
Sir-2.1 modulates 'calorie-restriction-mediated' prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease.Sir-2.1 调节“热量限制介导的”秀丽隐杆线虫神经退行性变的预防:对帕金森病的影响。
Biochem Biophys Res Commun. 2011 Sep 23;413(2):306-10. doi: 10.1016/j.bbrc.2011.08.092. Epub 2011 Aug 26.
6
Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.醋酸格拉替雷可能因其神经保护和抗炎作用而成为帕金森病的一种潜在治疗药物。
Med Hypotheses. 2007;69(6):1219-21. doi: 10.1016/j.mehy.2007.04.014. Epub 2007 Jun 4.
7
Does neurotrophic factor benefit to PD therapy via co-function with ubiquitin-proteasome system?神经营养因子是否通过与泛素-蛋白酶体系统的共同作用有益于 PD 的治疗?
Med Hypotheses. 2011 Apr;76(4):589-92. doi: 10.1016/j.mehy.2011.01.007. Epub 2011 Feb 1.
8
Neurotrophic factor therapy for Parkinson's disease.神经营养因子治疗帕金森病。
Prog Brain Res. 2010;184:237-64. doi: 10.1016/S0079-6123(10)84013-0.
9
Use of growth factors for the treatment of Parkinson's disease.生长因子在帕金森病治疗中的应用。
Expert Rev Neurother. 2010 Jun;10(6):915-24. doi: 10.1586/ern.10.55.
10
Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.帕金森病中的神经炎症:在神经退行性变和组织修复中的作用
Int J Neurosci. 2015;125(10):717-25. doi: 10.3109/00207454.2014.982795. Epub 2015 May 22.

引用本文的文献

1
Single-Cell Transcriptome Analyses of Four Pain Related Genes in Osteosarcoma.骨肉瘤中四个疼痛相关基因的单细胞转录组分析
Cancer Inform. 2025 Jul 19;24:11769351251331508. doi: 10.1177/11769351251331508. eCollection 2025.
2
Aerobic exercise-induced changes in fluid biomarkers in Parkinson's disease.有氧运动引起帕金森病患者体液生物标志物的变化。
NPJ Parkinsons Dis. 2025 Jul 1;11(1):190. doi: 10.1038/s41531-025-01042-8.
3
Materials approaches for next-generation encapsulated cell therapies.下一代封装细胞疗法的材料方法。
MRS Commun. 2025;15(1):21-33. doi: 10.1557/s43579-024-00678-6. Epub 2024 Dec 2.
4
The therapeutic use of clonal neural stem cells in experimental Parkinson´s disease.克隆神经干细胞在实验性帕金森病中的治疗应用。
Stem Cell Res Ther. 2024 Oct 9;15(1):356. doi: 10.1186/s13287-024-03965-0.
5
Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance.青光眼的神经保护:基础方面与临床相关性
J Pers Med. 2022 Nov 10;12(11):1884. doi: 10.3390/jpm12111884.
6
Self-Assembled Nanoscale Materials for Neuronal Regeneration: A Focus on BDNF Protein and Nucleic Acid Biotherapeutic Delivery.用于神经元再生的自组装纳米材料:聚焦脑源性神经营养因子蛋白和核酸生物治疗递送
Nanomaterials (Basel). 2022 Jun 30;12(13):2267. doi: 10.3390/nano12132267.
7
Dual effect of TAT functionalized DHAH lipid nanoparticles with neurotrophic factors in human BBB and microglia cultures.TAT 功能化 DHAH 脂质纳米粒对人 BBB 和小胶质细胞培养中神经营养因子的双重作用。
Fluids Barriers CNS. 2022 Mar 17;19(1):22. doi: 10.1186/s12987-022-00315-1.
8
Multifactoriality of Parkinson's Disease as Explored Through Human Neural Stem Cells and Their Transplantation in Middle-Aged Parkinsonian Mice.通过人类神经干细胞及其在中年帕金森病小鼠中的移植探索帕金森病的多因素性
Front Pharmacol. 2022 Jan 19;12:773925. doi: 10.3389/fphar.2021.773925. eCollection 2021.
9
Mechanistic Insight from Preclinical Models of Parkinson's Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy.帕金森病临床前模型的机制研究有助于重新调整 GDNF 治疗的临床试验努力。
Int J Mol Sci. 2021 Oct 28;22(21):11702. doi: 10.3390/ijms222111702.
10
Neurotrophic Factors in Parkinson's Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain.帕金森病中的神经营养因子:临床试验、公开挑战及纳米颗粒介导的脑内递送
Front Cell Neurosci. 2021 Jun 2;15:682597. doi: 10.3389/fncel.2021.682597. eCollection 2021.